非小细胞肺癌中核糖核苷酸还原酶亚单位M1表达及其与吉西他滨化学治疗敏感性相关研究

摘要

目的 分析非小细胞肺癌(NSCLC)石蜡包埋组织中核糖核苷酸还原酶(RR)亚单位M1(RRM1)表达与吉西他滨化学治疗敏感性的关系,并观察这项指标与患者生存的关系.方法 收集术后化学治疗应用吉西他滨的NSCLC患者的病理标本制成组织芯片,采用免疫组织化学法检测RRM1的表达,并分析患者的化学治疗疗效和生存资料与上述指标表达的关系.结果 在50例病理组织中RRM1过表达22例(44%).RRM1过表达组的1 a生存率小于非过表达组的1 a生存率(P＜0.05).不同年龄、性别、病理类型及肿瘤部位的2组患者RRM1表达差别无统计学意义(P＞0.05),不同分化程度、不同肿瘤大小、淋巴结转移情况及分期的2组患者RRM1表达差别有统计学意义(P＜0.05).RRM1非过表达组织化学治疗有效率82.1%(23/28)高于RRM1过表达组有效率22.7%(5/22),差别有统计学意义(P＜0.05).RRM1过表达组的1 a生存率为53.6%(15/28),非过表达组1 a生存率为77.3%(17/22),RRM1过表达组的1 a生存率低于RRM1非过表达组(P＜0.05).结论 NSCLC患者中RRM1低表达的患者生存率高于高表达的患者,RRM1可以作为NSCLC采用吉西他滨方案化学治疗敏感性和生存预测的分子指标.%Objective To analyze the relationship between the expression of ribonucleotide reductase M1 ( RRM1 )and the sensitive of gemcitabine chemotherapy in non-small-cell lung cancer ( NSCLC) , and observe the relationship between the expression of RRM1 and the patients' survival. Methods Paraffin-embedded pathological tissues of patients which were given gemcitabine chemotherapy after operation were collected and made tissue array. The expression of RRM1 in tumor samples was examined by immunohistochemical method. Therapeutic effect and the relationship between survival data and above-mentioned expressions were analyzed. Results Among these 50 patients,over expression rate of RRM1 was 44％ (22/50). The one year survival rate in over-expression group was lower than that in non over-expression group (P ＜0.05). There were no statistic significance of RRM1 expression in different age,gender, the type of pathology tissue and tumor site between over-expression group and non over-expression group(P＞0.05). There were statistic significance of RRM1 expression in patients of different differentiation,different tumor sizes,lymphaden diversion and stages between over-expression group and non over-expression group(P ＜ 0.05). The effective rate of chemotherapy in non over-expression group was 82.1 ％ (23/28) and significantly higher than that in over-expression group which was 22. 7％ (5/22) (P ＜0. 05). The one year survival rate in over-expression group was 53.6％ ,and was significantly lower than that in non over-expression group which was 77.3％ (P ＜0.05). Conclusion Survival rate in non over-expression group of RRM1 was higher than that in over-expression group;Therefore,RRM1 can be used as a molecular index of gemcitabine chemotherapy sensitivity and prognosis in NSCLC patients.